Furthermore, in Paez et al.'s study [15], they found that EGFR mutations were more frequent in adenocarcinoma patients (21% versus 2%), in women (20% versus 9%), and in Japanese patients (26% versus 2%). Here, EGFR is linked to adenocarcinoma.